An adenylate cyclase inhibitor in the treatment of excited psychosis

Gregory Roitman, Joseph Levine, Yuly Bersudsky, R. H. Belmaker

    Research output: Contribution to journalArticlepeer-review

    4 Scopus citations


    The authors examined the advantage of addition of the adenylate cyclase inhibitor demeclocycline (DMC), versus placebo to haloperidol therapy in the treatment of excited psychosis. Sixteen manic or excited schizoaffective patients completed a double-blind controlled five week trial. Nine patients were assigned to DMC and haloperidol and seven patients were assigned to placebo and haloperidol. Brief Psychiatric Rating Scale (BPRS) was used as an assessment tool at baseline, 1, 2, 3, 4 and 5 weeks. BPRS scores showed no significant difference between the two study groups. However, the reduction in BPRS score was 23.5 units in the DMC group and 16·7 units in the placebo group; power analysis showed that this trend would be significant if the size of the study were doubled. Adenylate cyclase inhibitors might have a therapeutic role in the treatment of excited psychosis.

    Original languageEnglish
    Pages (from-to)121-125
    Number of pages5
    JournalHuman Psychopharmacology
    Issue number2
    StatePublished - 1 Mar 1998


    • Adenylate cyclase
    • Demeclocycline
    • Excited psychosis
    • Haloperidol
    • Mania
    • Schizoaffective disorder

    ASJC Scopus subject areas

    • Neurology
    • Clinical Neurology
    • Psychiatry and Mental health
    • Pharmacology (medical)


    Dive into the research topics of 'An adenylate cyclase inhibitor in the treatment of excited psychosis'. Together they form a unique fingerprint.

    Cite this